Mizuho Securities USA’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mizuho Securities USA’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-19,500	Closed	-$1.67M	–	138
2019 Q2	$1.67M	Buy	19,500 +4,416	+29%	+$378K	0.08%	78
2019 Q1	$1.34M	Sell	15,084 -10,190	-40%	-$944K	0.1%	76
2018 Q4	$2.15M	Buy	25,274 +13,371	+112%	+$1.27M	0.29%	56
2018 Q3	$1.15M	Buy	+11,903	New	+$1.19M	0.09%	87

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Mizuho Securities USA's BMRN Position: Q3 2019 in Review

Mizuho Securities USA sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 19,500 shares — an estimated $1.67M sold.

Mizuho Securities USA first reported a position in BMRN in Q3 2018 and held it in 4 quarters. The position peaked at $2.15M in Q4 2018. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Mizuho Securities USA reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Mizuho Securities USA sold 19,500 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $1.67M.
Mizuho Securities USA first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 4 quarters.
Mizuho Securities USA's BioMarin Pharmaceuticals position peaked at $2.15M in Q4 2018.
436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Mizuho Securities USA's 13F filing for Q3 2019, filed 31 Oct 2019.